乳腺与甲状腺外科学术论文

1. 段学宁,白文佩,杨慕坤,顾蓓,李艳萍等. 乳腺癌患者选择性雌激素受体调节剂治疗相关子宫内膜安全管理的中国专家共识。2021,4(42）:672-677.

2. Yinjuan Li ,Lu Qi, Yu Wang, Yanping Li *.Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: An open, phase I dose-escalation study. Anticancer Drugs.. 2023 1;34(6):763-774. (IF 2.389)

3. Wu M, Yuan K, Lyu S, Li Y*. Screening potential immune signatures for early-stage basal-like/triple-negative breast cancer. World J Surg Oncol. 2022 Jun 24;20(1):214. (IF 3.25)

4. Yuan K, Wu J, Zhao Y, Lyu S, Zhou Q, Shi F, Li Y*, Song Q. Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. Diagn Pathol. 2022 Sep 10;17(1):68. (IF 3.19 )

5. Yuan K, Wu M, Lyu S, Li Y*. Identification of prognostic genes for early basal-like breast cancer with weighted gene co-expression network analysis. Medicine (Baltimore). 2022 Oct 21;101(42):e30581. (IF 1.81)

6. 袁可玉,宋清坤,吕淑贞,李艳萍*。外周血PD-1/PD-L1在乳腺癌中的研究进展。肿瘤代谢与营养电子杂志. 2021, 8(03): 326-331.

7. Yu Feng. Yanping Li*. Long disease-free survival (48 months) in a breast cancer patient  with ovarian and pelvic metastasis—a case report.     Translational Cancer Research. Transl Cancer Res,. 2020 Dec;9(12):7669-7675. (IF 0.496)

8. 冯宇，李艳萍，张曼. 乳腺癌伴二型糖尿病的特征分析.标记免疫分析与临床.2019,5(26):722-725.

9. 刘永波,郭怡辉,李艳萍. 三阴乳腺癌细胞中Atg13基因的过表达与化疗耐药的研究. 肿瘤代谢与营养,2019,6(3)310-315.

10. Yu Feng, Yunchao Wang, Xia Zhao, Ying Mu, Shuzhen Lv, Yanping Li*.Correlation between the intrinsic subtype and diagnostic methods of axillary lymph node metastasis in primary breast cancer. EJGO,2018(6):921-925.

11. Lv S, Wang Y, Sun T, Wan D, Sheng L, Li W, Zhu H, Li Y*, Lu J. Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis. Oncol Res Treat. 2018;41(7-8):450-455.

12. Y. Mu , Y. Chen , X. Zhao , Y. Feng , D. Wang , A.I. Riker , Y. Li* . Occult breast cancer presenting as a mediastinal mass:case report and review of the literature. EJGO,2018(2):300-303.

13. Yunchao W, Yanping L1*,Janice Lu*, et al. Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study. Onco Targets and Therapy 2015，8：3337-3348.

14. Yunchao W, Yanping L*,Janice Lu*, et al. Prognostic significance of Ubiquilin1 expression in invasive breast cancer. Cancer Biomark. 2015 ，15(5):635-643.

15. 吕淑贞，李艳萍，吕大鹏等.31例原发性双侧乳腺癌患者的临床特征分析，癌症进展，2018,16（4）：452-454.

16. 吕淑贞，李艳萍，赵霞等.静脉留置针持续负压引流治疗乳腺癌术后皮下积液，癌症进展，2018,16(1):120-122.

17. 吕淑贞，谢苗苗，李艳萍.X线钼靶联合超声检查在乳腺肿块鉴别诊断中的价值，中国老年学杂志，2018,38(5):1105-1107.

18. 吕淑贞，李艳萍，赵霞等. 乳腺癌组织PD1、PDL1表达变化及其与患者临床病理参数和预后的关系，山东医药，2018,58(28):28-31.

19. 汪云超,穆颖,李艳萍等.乳腺癌治疗过程中激素受体、HER2受体转变一例[J].中华内分泌外科杂,2015,(2):171-172.

20. 汪云超,李艳萍.人表皮生长因子受体-2阳性乳腺癌靶向治疗新进展[J].中华内分泌外科杂,2015,(5):428-431.

21. 黄静 李艳萍.骨代谢指标在乳腺癌骨转移的临床应用.中国肿瘤临床与康复. 2013,20(1):27-29.

22. 冯宇，李艳萍.乳腺钼靶X线三维立体定位系统引导下导丝定位活检的临床应用[J].中华普通外科文献.2016(10):192-194.

23. 冯宇，李艳萍.表柔比星联合多西他赛新辅助化疗对乳腺癌患者组织ki-67表达的影响及意义[J].山东医药.2016,56,24:63-65.

24. 冯宇，李艳萍.腋窝前哨淋巴结活检在原发性乳腺癌患者中的应用价值[J]. 山东医药.2016,56,16:68-70.

25. 付慧，李艳萍.Ubiquilin蛋白在乳腺癌组织中的表达与预后意义，肿瘤防治研究，2017,44(8):535-539.